Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part D growth through MA plans

Executive Summary

Membership in Medicare Advantage drug plans increased approximately 6 percent to 8 million following the 2008 open enrollment period, according to CMS enrollment data. Enrollment in stand-alone Medicare prescription drug plans rose by about 1.2 percent to 17.4 million. The largest gain in the MA-PD market was recorded by Humana, adding 92,000 to a total of 1.2 million, based on an analysis of enrollment numbers by Avalere Health. Market leader UnitedHealth added 21,600 MA-PD members for a total of approximately 1.3 million. However, UnitedHealth lost nearly 600,000 stand-alone PDP members in 2008 (to 4.1 million) and Humana lost about 290,000, to 3.2 million. Due to premium increases, United predicted it would lose up to 650,000 low-income PDP members in 2008 (1"The Pink Sheet," Oct. 1, 2007, p. 12). Humana also had forecast losses based on higher premiums (2"The Pink Sheet," Oct. 8, 2007, p. 18)...

You may also be interested in...

Part D Rule Reduces Plan Reassignments For Low-Income Enrollees

CMS' new approach to setting the premium "benchmark" for low-income enrollees in Medicare drug plans will trim the number of enrollees who are reassigned each year - but not eliminate the issue

Part D Low-Income Enrollee Shifts: United May Lose 650,000 Members In 2008

Next year UnitedHealth Group may lose 650,000 of the auto-assigned low-income members currently enrolled in its stand-alone Medicare prescription drug plans

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts